{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:35:30Z","timestamp":1789598130522,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["CNS2022-135327"],"award-info":[{"award-number":["CNS2022-135327"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-01511-3","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T05:37:55Z","timestamp":1746855475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unit"],"prefix":"10.1038","volume":"15","author":[{"given":"Lourdes","family":"\u00c1lvarez-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Pe\u00f1a-Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ferr\u00e9-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Balaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n Luis","family":"Amengual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Baquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Ch\u00e1fer-Peric\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"1511_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/alz.13016","volume":"19","author":"Alzheimer\u2019s disease facts and figures","year":"2023","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement. 19, 1598\u20131695 (2023).","journal-title":"Alzheimer\u2019s Dement."},{"key":"1511_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 14, 535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018 (2018).","journal-title":"Alzheimer\u2019s Dement."},{"key":"1511_CR3","first-page":"111","volume":"8","author":"S Engelborghs","year":"2017","unstructured":"Engelborghs, S. et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer\u2019s Dement. Diagn. Assess. Dis. Monit. 8, 111\u2013126 (2017).","journal-title":"Alzheimer\u2019s Dement. Diagn. Assess. Dis. Monit."},{"key":"1511_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/jpm10030061","volume":"10","author":"C Villa","year":"2020","unstructured":"Villa, C., Lavitrano, M., Salvatore, E. & Combi, R. Molecular and imaging biomarkers in Alzheimer\u2019s disease: A focus on recent insights. J. Pers. Med. 10, 61 (2020).","journal-title":"J. Pers. Med."},{"key":"1511_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101544","volume":"74","author":"YAR Mahaman","year":"2022","unstructured":"Mahaman, Y. A. R. et al. Biomarkers used in Alzheimer\u2019s disease diagnosis, treatment, and prevention. Ageing Res. Rev. 74, 101544 (2022).","journal-title":"Ageing Res. Rev."},{"key":"1511_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40035-024-00432-x","volume":"13","author":"E Liu","year":"2024","unstructured":"Liu, E., Zhang, Y. & Wang, J.-Z. Updates in Alzheimer\u2019s disease: from basic research to diagnosis and therapies. Transl. Neurodegener. 13, 45 (2024).","journal-title":"Transl. Neurodegener."},{"key":"1511_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/ADR-230029","volume":"7","author":"MV Pais","year":"2023","unstructured":"Pais, M. V., Forlenza, O. V. & Diniz, B. S. Plasma biomarkers of Alzheimer\u2019s disease: A review of available assays, recent developments, and implications for clinical practice. J. Alzheimers Dis. Rep. 7, 355\u2013380 (2023).","journal-title":"J. Alzheimers Dis. Rep."},{"key":"1511_CR8","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira, J. B. et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain 144, 3505\u20133516 (2021).","journal-title":"Brain"},{"key":"1511_CR9","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke, M. M. et al. Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 78, 1108 (2021).","journal-title":"JAMA Neurol."},{"key":"1511_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault, J. et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 80, 188 (2023).","journal-title":"JAMA Neurol."},{"key":"1511_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/alz.12447","volume":"18","author":"P Chatterjee","year":"2022","unstructured":"Chatterjee, P. et al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 18, 1141\u20131154 (2022).","journal-title":"Alzheimer\u2019s Dement."},{"key":"1511_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40035-021-00234-5","volume":"10","author":"X Ding","year":"2021","unstructured":"Ding, X. et al. Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer\u2019s disease: a systematic review and meta-analysis. Transl. Neurodegener. 10, 10 (2021).","journal-title":"Transl. Neurodegener."},{"key":"1511_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cca.2022.03.018","volume":"531","author":"J Telser","year":"2022","unstructured":"Telser, J., Risch, L., Saely, C. H., Grossmann, K. & Werner, P. P-tau217 in Alzheimer\u2019s disease. Clin. Chim. Acta 531, 100\u2013111 (2022).","journal-title":"Clin. Chim. Acta"},{"key":"1511_CR14","doi-asserted-by":"crossref","unstructured":"Salvad\u00f3, G. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol. Med. 15, (2023).","DOI":"10.15252\/emmm.202217123"},{"key":"1511_CR15","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack, C. R. et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s Dement. 20, 5143\u20135169 (2024).","journal-title":"Alzheimer\u2019s Dement."},{"key":"1511_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106175","volume":"183","author":"A Snellman","year":"2023","unstructured":"Snellman, A. et al. Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer\u2019s disease. Neurobiol. Dis. 183, 106175 (2023).","journal-title":"Neurobiol. Dis."},{"key":"1511_CR17","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146, 1592\u20131601 (2023).","journal-title":"Brain"},{"key":"1511_CR18","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R., van der Kant, R. & Hansson, O. Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726\u2013734 (2022).","journal-title":"Lancet Neurol."},{"key":"1511_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.apsb.2021.10.002","volume":"12","author":"BR Troutwine","year":"2022","unstructured":"Troutwine, B. R., Hamid, L., Lysaker, C. R., Strope, T. A. & Wilkins, H. M. Apolipoprotein E and Alzheimer\u2019s disease. Acta Pharm. Sin. B 12, 496\u2013510 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"1511_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.arr.2017.06.002","volume":"37","author":"P Huebbe","year":"2017","unstructured":"Huebbe, P. & Rimbach, G. Evolution of human apolipoprotein E (APOE) isoforms: Gene structure, protein function and interaction with dietary factors. Ageing Res. Rev. 37, 146\u2013161 (2017).","journal-title":"Ageing Res. Rev."},{"key":"1511_CR21","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer, L. A. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA 278, 1349 (1997).","journal-title":"JAMA"},{"issue":"261","key":"1511_CR22","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"1979","author":"EH Corder","year":"1993","unstructured":"Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science 1979(261), 921\u2013923 (1993).","journal-title":"Science"},{"key":"1511_CR23","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler, S. E. et al. Acceptable performance of blood biomarker tests of amyloid pathology\u2014recommendations from the Global CEO Initiative on Alzheimer\u2019s disease. Nat. Rev. Neurol. 20, 426\u2013439 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"1511_CR24","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqembi."},{"key":"1511_CR25","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s40265-024-02087-4","volume":"84","author":"C Kang","year":"2024","unstructured":"Kang, C. Donanemab: First approval. Drugs 84, 1313\u20131318 (2024).","journal-title":"Drugs"},{"key":"1511_CR26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40265-023-01851-2","volume":"83","author":"S Hoy","year":"2023","unstructured":"Hoy, S. M. Lecanemab: First approval. Drugs 83, 359\u2013365 (2023).","journal-title":"Drugs"},{"key":"1511_CR27","doi-asserted-by":"publisher","first-page":"17557","DOI":"10.1038\/s41598-024-66195-7","volume":"14","author":"W Li","year":"2024","unstructured":"Li, W., Sun, L., Yue, L. & Xiao, S. Diagnostic and predictive power of plasma proteins in Alzheimer\u2019s disease: a cross-sectional and longitudinal study in China. Sci. Rep. 14, 17557 (2024).","journal-title":"Sci. Rep."},{"key":"1511_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.118996","volume":"558","author":"S Torres Robledillo","year":"2024","unstructured":"Torres Robledillo, S. et al. Validation of plasma biomarkers in Alzheimer disease. Clin. Chim. Acta 558, 118996 (2024).","journal-title":"Clin. Chim. Acta"},{"key":"1511_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","volume":"16","author":"J Arranz","year":"2024","unstructured":"Arranz, J. et al. Diagnostic performance of plasma pTau217, pTau181, A\u03b21-42 and A\u03b21-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimers Res. Ther. 16, 139 (2024).","journal-title":"Alzheimers Res. Ther."},{"key":"1511_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 81, 255 (2024).","journal-title":"JAMA Neurol."},{"key":"1511_CR31","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00415-023-12148-5","volume":"271","author":"AJ Mendes","year":"2024","unstructured":"Mendes, A. J. et al. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J. Neurol. 271, 2053\u20132066 (2024).","journal-title":"J. Neurol."},{"key":"1511_CR32","doi-asserted-by":"crossref","unstructured":"Brum, W. S. et al. A three\u2010range approach enhances the prognostic utility of CSF biomarkers in Alzheimer\u2019s disease. Alzheimer\u2019s & Dement. Transl. Res. Clin. Interv. 8, (2022).","DOI":"10.1002\/trc2.12270"},{"key":"1511_CR33","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/alz.13525","volume":"20","author":"F Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz, F. et al. A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 20, 1239\u20131249 (2024).","journal-title":"Alzheimer\u2019s Dement."},{"key":"1511_CR34","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen, E. H. et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 20, 739\u2013752 (2021).","journal-title":"Lancet Neurol."},{"key":"1511_CR35","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton, N. J. et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat. Med. 28, 2555\u20132562 (2022).","journal-title":"Nat. Med."},{"key":"1511_CR36","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton, N. J. et al. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. Alzheimer\u2019s Dement. 19, 1913\u20131924 (2023).","journal-title":"Alzheimer\u2019s Dement."},{"key":"1511_CR37","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s43587-023-00405-1","volume":"3","author":"L Montoliu-Gaya","year":"2023","unstructured":"Montoliu-Gaya, L. et al. Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nat. Aging 3, 661\u2013669 (2023).","journal-title":"Nat. Aging"},{"key":"1511_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5114\/fn.2019.85929","volume":"57","author":"A Armstrong","year":"2019","unstructured":"Armstrong, A. Risk factors for Alzheimer\u2019s disease. Folia Neuropathol. 57, 87\u2013105 (2019).","journal-title":"Folia Neuropathol."},{"key":"1511_CR39","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/alz.13539","volume":"20","author":"PM Cogswell","year":"2024","unstructured":"Cogswell, P. M. et al. Modeling the temporal evolution of plasma p-tau in relation to amyloid beta and tau PET. Alzheimer\u2019s Dement. 20, 1225\u20131238 (2024).","journal-title":"Alzheimer\u2019s Dement."},{"key":"1511_CR40","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/brain\/awad042","volume":"146","author":"CR Jack","year":"2023","unstructured":"Jack, C. R. et al. Predicting amyloid PET and tau PET stages with plasma biomarkers. Brain 146, 2029\u20132044 (2023).","journal-title":"Brain"},{"key":"1511_CR41","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum, W. S. et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat. Aging 3, 1079\u20131090 (2023).","journal-title":"Nat. Aging"},{"key":"1511_CR42","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1002\/alz.13697","volume":"20","author":"H Huber","year":"2024","unstructured":"Huber, H. et al. Biomarkers of Alzheimer\u2019s disease and neurodegeneration in dried blood spots\u2014A new collection method for remote settings. Alzheimer\u2019s Dement. 20, 2340\u20132352 (2024).","journal-title":"Alzheimer\u2019s Dement."},{"key":"1511_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cca.2015.05.024","volume":"449","author":"A Fourier","year":"2015","unstructured":"Fourier, A. et al. Pre-analytical and analytical factors influencing Alzheimer\u2019s disease cerebrospinal fluid biomarker variability. Clin. Chim. Acta 449, 9\u201315 (2015).","journal-title":"Clin. Chim. Acta"},{"key":"1511_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2010\/986310","volume":"2010","author":"M Bjerke","year":"2010","unstructured":"Bjerke, M. et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J. Alzheimers Dis. 2010, 1\u201311 (2010).","journal-title":"Int J. Alzheimers Dis."},{"key":"1511_CR45","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1373\/clinchem.2005.058776","volume":"52","author":"P Lewczuk","year":"2006","unstructured":"Lewczuk, P. et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid \u03b2 peptides. Clin. Chem. 52, 332\u2013334 (2006).","journal-title":"Clin. Chem."},{"key":"1511_CR46","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1212\/01.wnl.0000256043.50901.e3","volume":"68","author":"RJ Bateman","year":"2007","unstructured":"Bateman, R. J., Wen, G., Morris, J. C. & Holtzman, D. M. Fluctuations of CSF amyloid-\u03b2 levels. Neurology 68, 666\u2013669 (2007).","journal-title":"Neurology"},{"key":"1511_CR47","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13195-024-01503-x","volume":"16","author":"A Ordu\u00f1a Dolado","year":"2024","unstructured":"Ordu\u00f1a Dolado, A. et al. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer\u2019 disease biomarkers. Alzheimers Res. Ther. 16, 132 (2024).","journal-title":"Alzheimers Res. Ther."},{"key":"1511_CR48","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette, A. et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimer\u2019s Dement. 19, 1403\u20131414 (2023).","journal-title":"Alzheimer\u2019s Dement."},{"key":"1511_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2020.102212","volume":"26","author":"A Vasilevskaya","year":"2020","unstructured":"Vasilevskaya, A. et al. Interaction of APOE4 alleles and PET tau imaging in former contact sport athletes. Neuroimage Clin. 26, 102212 (2020).","journal-title":"Neuroimage Clin."},{"key":"1511_CR50","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cell.2016.12.044","volume":"168","author":"Y-WA Huang","year":"2017","unstructured":"Huang, Y.-W.A., Zhou, B., Wernig, M. & S\u00fcdhof, T. C. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and A\u03b2 secretion. Cell 168, 427-441.e21 (2017).","journal-title":"Cell"},{"key":"1511_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.119876","volume":"562","author":"L Agnello","year":"2024","unstructured":"Agnello, L. et al. Exploring the effect of APOE \u03b54 on biomarkers of neurodegeneration in Alzheimer\u2019s disease. Clin. Chim. Acta 562, 119876 (2024).","journal-title":"Clin. Chim. Acta"},{"key":"1511_CR52","doi-asserted-by":"crossref","unstructured":"Bornhorst, J. A. et al. Quantitative assessment of the effect of chronic kidney disease on plasma P-Tau217 concentrations. Neurology 104, (2025).","DOI":"10.1212\/WNL.0000000000210287"},{"key":"1511_CR53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13195-025-01692-z","volume":"17","author":"B Arslan","year":"2025","unstructured":"Arslan, B. et al. The impact of kidney function on Alzheimer\u2019s disease blood biomarkers: implications for predicting amyloid-\u03b2 positivity. Alzheimers Res. Ther. 17, 48 (2025).","journal-title":"Alzheimers Res. Ther."},{"key":"1511_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2023.341535","volume":"1273","author":"M-V Tieu","year":"2023","unstructured":"Tieu, M.-V., Choi, S. H., Le, H. T. N. & Cho, S. Electrochemical impedance-based biosensor for label-free determination of plasma P-tau181 levels for clinically accurate diagnosis of mild cognitive impairment and Alzheimer\u2019s disease. Anal. Chim. Acta 1273, 341535 (2023).","journal-title":"Anal. Chim. Acta"},{"key":"1511_CR55","doi-asserted-by":"crossref","unstructured":"Verberk, I. M. W. et al. F2\u201007\u201004: Plasma amyloid beta 1\u201342 and 1\u201340 measured by a novel simoa assay as a diagnostic tool for Alzheimer\u2019s disease pathology. Alzheimer\u2019s Dement. 15, (2019).","DOI":"10.1016\/j.jalz.2019.06.4443"},{"key":"1511_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2024.100721","volume":"23","author":"J Gobom","year":"2024","unstructured":"Gobom, J., Brinkmalm, A., Brinkmalm, G., Blennow, K. & Zetterberg, H. Alzheimer\u2019s disease biomarker analysis using targeted mass spectrometry. Mol. Cell. Proteomics 23, 100721 (2024).","journal-title":"Mol. Cell. Proteomics"},{"key":"1511_CR57","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.3390\/jcm13164735","volume":"13","author":"M Baquero","year":"2024","unstructured":"Baquero, M. et al. Insights from a 7-Year Dementia Cohort (VALCODIS): ApoE genotype evaluation. J. Clin. Med. 13, 4735 (2024).","journal-title":"J. Clin. Med."},{"key":"1511_CR58","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a\u2010Bautista, C. et al. Clinical usefulness of cerebrospinal fluid biomarkers in Alzheimer\u2019s disease. Eur. J. Clin. Investig. 53, (2023).","DOI":"10.1111\/eci.13910"},{"key":"1511_CR59","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456\u20132477 (2011).","journal-title":"Brain"},{"key":"1511_CR60","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. Neurology 76, 1006\u20131014 (2011).","journal-title":"Neurology"},{"key":"1511_CR61","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WAD.0000000000000034","volume":"28","author":"P Sachdev","year":"2014","unstructured":"Sachdev, P. et al. Diagnostic criteria for vascular cognitive disorders. Alzheimer Dis. Assoc. Disord. 28, 206\u2013218 (2014).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"1511_CR62","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"1511_CR63","unstructured":"https:\/\/www.roche-as.es\/lightmix_global."},{"key":"1511_CR64","unstructured":"R Foundation for Statistical Computing, V. Austria. R: A Language and Environment for Statistical Computing. (2023)."},{"key":"1511_CR65","doi-asserted-by":"crossref","unstructured":"Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, (2010).","DOI":"10.18637\/jss.v033.i01"},{"key":"1511_CR66","doi-asserted-by":"crossref","unstructured":"Kuhn, M. Building predictive models in R using the caret package. J. Stat. Softw. 28, (2008).","DOI":"10.18637\/jss.v028.i05"},{"key":"1511_CR67","doi-asserted-by":"crossref","unstructured":"Thiele, C. & Hirschfeld, G. cutpointr\u202f: Improved estimation and validation of optimal cutpoints in R. J. Stat. Softw. 98, (2021).","DOI":"10.18637\/jss.v098.i11"},{"key":"1511_CR68","doi-asserted-by":"publisher","unstructured":"Wickham, H. Ggplot2. https:\/\/doi.org\/10.1007\/978-3-319-24277-4 (Springer International Publishing, 2016).","DOI":"10.1007\/978-3-319-24277-4"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01511-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T07:02:05Z","timestamp":1746860525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01511-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1511"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-01511-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee from Instituto de Investigaci\u00f3n Sanitaria La Fe (Valencia, Spain) (Reference number: 2022-990-1).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement standard"}},{"value":"All participants signed informed consent prior to their recruitment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"16316"}}